Organigram Global (TSE:OGI)
TSX:OGI
Earnings Data
Report Date
Apr 14, 2026TBA (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
-0.01Last Year’s EPS
0.32Same Quarter Last Year
Strong Buy
Based on 4 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call conveyed substantial operational and financial progress: strong year-over-year revenue (+49%), adjusted gross profit (+67%), adjusted EBITDA (+273%), cultivation scale gains (+43% harvested kg), and important plant-science and manufacturing advances. Management emphasized recovery from discrete disruptions (BC strike, out-of-spec international flower) and reiterated full-year guidance (> $300M revenue) and confidence in margin expansion. Key risks include a roughly $3.5M international revenue impact from out-of-spec flower (now being repurposed domestically), elevated competition in vapes/IPRs, near-term working capital-driven cash usage, pending EU GMP timing, and slow U.S. penetration. Overall, the positive financial momentum, margin improvement, operational breakthroughs and clear mitigation plans outweigh the temporary operational and market headwinds.Company Guidance
Strong Revenue Growth
Net revenue increased 49% year-over-year to $65.3 million (Q1 FY2026 vs Q1 FY2025), driven by Canadian growth, Motif integration and higher international sales; sequential revenue was down 21% due to seasonality and one-time disruptions.
Material Margin and Profit Improvements
Adjusted gross profit rose 67% to $23.9 million and adjusted gross margin held steady at 38% sequentially, up ~500 basis points year-over-year. Adjusted EBITDA improved 273% to $5.3 million.
Return to Net Income
Reported net income of $20 million in Q1 versus a $23 million net loss in the prior year quarter, a $43 million year-over-year improvement primarily driven by changes in fair value of derivative liabilities and other non-operating items.
Market Leadership in Canada
Organigram maintained the #1 total market share position in Canada with 11.3% share in Q1 and 11.7% over the past 12 months. The company holds #1 positions in Ontario, British Columbia and Alberta, and strong provincial shares (e.g., 33.1% New Brunswick, 30.4% Saskatchewan).
Top Performing Brands and Retail Sales
Three brands (SHRED, BOXHOT, Big Bag O' Buds) stayed in the top 10 and generated over $67 million in retail sales; SHRED became the #2 gummy brand nationally in December and BOXHOT/Organigram Innovation are #1 dabbable concentrate with 15.5% category share.
Operating and Cultivation Scale Gains
Harvested >28,000 kg of flower in Q1, a 43% year-over-year increase. Average flower THC reached a quarterly high of >29% with 38% of lots testing >30% THC. LED lighting conversion and nutrient refinements drove yield improvement.
Plant-Science Breakthroughs
Proprietary genetic marker for powdery mildew resistance announced, reducing screening time from ~90 days to ~10 days, enabling earlier removal of out-of-spec plants and expected to improve realized yields and lower waste.
Manufacturing and Capacity Improvements
100% hydrocarbon extraction with capacity up 87% year-over-year and lower associated COGS; beverage production line commissioned in Winnipeg with beginning in-house production; Motif synergies contributing to lower-cost inventory flow-through.
International Sales Growth and Distribution Progress
International sales in Q1 were $5 million, up ~51–55% year-over-year. Progress on branded international rollouts includes vape production in Australia and launches of Collective Project and Fetch in Illinois and Wisconsin expanding U.S. footprint to 11 states; products available in 20+ states via DTC and retail channels.
Liquidity and Cash Generation Trends
Cash and short-term investments totaled $63 million (including $7.6 million unrestricted). Cash provided by operating activities before working capital changes was $0.3 million versus cash used of $6.3 million in the prior year quarter; management expects positive free cash flow for the fiscal year.
On-Track Full-Year Guidance
Management reiterated confidence in delivering against full-year guidance of revenue exceeding $300 million and expects margin expansion as higher-margin international volumes scale through the back half of the year.
TSE:OGI Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
TSE:OGI Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Feb 10, 2026 | C$2.17 | C$1.89 | -12.90% |
Dec 16, 2025 | C$2.46 | C$2.61 | +6.10% |
Aug 13, 2025 | C$2.22 | C$2.21 | -0.45% |
May 12, 2025 | C$1.64 | C$1.80 | +9.76% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Organigram Global (TSE:OGI) report earnings?
Organigram Global (TSE:OGI) is schdueled to report earning on Apr 14, 2026, TBA (Confirmed).
What is Organigram Global (TSE:OGI) earnings time?
Organigram Global (TSE:OGI) earnings time is at Apr 14, 2026, TBA (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is TSE:OGI EPS forecast?
TSE:OGI EPS forecast for the fiscal quarter 2026 (Q2) is -0.01.